DRUG
Thymosin Alpha1
Drug interventions have been done in previous clinical studies
Long-term Prognosis of Patients With Sepsis After Immunotherapy
Status
Not yet recruiting
Phase
Not applicable
Enrollment
900
Locations
0
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term outcomes (3 year mortality) of patients with sepsis after immunotherapy. Based on the preliminary clinical study (NCT02867267), this study will conduct long-term follow-up for sepsis patients to provide data support for the long-term prognosis of immunotherapy.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
May 25, 2021
Study start
Jul 1, 2021
Primary completion
Dec 31, 2026
Study completion
Mar 31, 2027
Results posted
Not reported
Registry updated
May 25, 2021
Outcomes
What the study measures.
Primary outcomes
three years mortality
Time frame · 3 years
Mortality rate of patients treated with thymosin α1 or placebo within 3 years
Secondary outcomes
Recurrence rate of sepsis
Time frame · 5 years
Percentage of recurrent sepsis within 5 years of discharge sepsis patients
one year mortality
Time frame · 1 year
Mortality rate of patients treated with thymosin α1 or placebo within 1 year
Five years mortality
Time frame · 5 years
Mortality rate of patients treated with thymosin α1 or placebo within 5 years
short form 36 questionnaire
Time frame · 1 year
Quality of life of sepsis patients after 1 year of thymosin α1 or placebo treatment
Eligibility
Who can take part.
- Minimum age
- Not reported
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Sepsis patients in the TESTS study Patients who discharged from hospital after recovery Exclusion Criteria: * None
Study locations
0 registered sites.
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Thymosin Alpha-1.
NCT IDStudyPhase / statusEnrollmentUpdated
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
The Methodist Hospital Research Institute · Vaccine Response · COVID-19 Vaccine
Phase 1
Recruiting
75
2026-07
Thymosin-α1 for Recurrent Implantation Failure
Fakih IVF Fertility Center · Recurrent Implantation Faliure
Phase 2 / Phase 3
Recruiting
136
2026-06
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer
Beijing Friendship Hospital · Colorectal Neoplasms
Not applicable
Completed
47
2026-06
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
Sun Yat-sen University · Melanoma · Immune-related Adverse Event
Phase 2
Recruiting
55
2026-06
TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma
Fudan University · Esophageal Squamous Cell Carcinoma
Not applicable
Active, not recruiting
50
2026-04
Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients
William B. Ershler, MD · COVID-19
Phase 2
Completed
189
2026-04
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University · Gastric Cancer
Phase 2
Recruiting
48
2026-03
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Zekuan Xu · Gastric Cancer · Esophagogastric Junction Adenocarcinoma
Phase 2
Recruiting
30
2026-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.